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Impact of FLT3 mutations and secondary
cytogenetic changes on the outcome of patients
with newly diagnosed acute promyelocytic
leukemia treated with a single agent arsenic
trioxide regimen 
Ninety-eight newly diagnosed cases of PML-
RARα positive APL were treated with a regimen of
single agent ATO. FLT3 activating mutations were
seen in 33% and an additional cytogenetic finding
was noted in 23.2%. FLT3 activating mutations
were significantly associated with a bcr3 PML-
RARα isoform (p=0.012) and a delay in achieving a
molecular remission (p=0.022). Neither FLT3 acti-
vating mutations nor secondary cytogenetic
changes had an impact on clinical outcome. Haematologica 2007; 92:994-995
The efficacy of arsenic trioxide (ATO) in the manage-
ment of relapsed and newly diagnosed cases of acute
promyelocytic leukemia (APL) has been established.1,2
Fms-like tyrosine kinase 3 (FLT3) mutations are common-
ly seen in patients with APL.3 The common activating
mutations of FLT3 include the FLT3 internal tandem
duplication (FLT3-ITD) and a point mutation in the acti-
vation loop (D835V).3 A retrospective analysis of the
impact of FLT3 mutations in patients with APL, treated
with conventional ATRA plus chemotherapy regimens,
reported a higher incidence of induction deaths in one
study4 while another study reported a trend towards a
shorter overall survival.5 Secondary cytogenetic changes
have been reported to have an adverse impact in some
subsets of AML.6 However, a similar adverse effect was
not reported in patients with APL treated with conven-
tional chemotherapy.7,8 We undertook a retrospective
analysis to study the impact of these factors on the out-
come of 98 patients with newly diagnosed promyelocytic
leukemia/retinoic acid receptor α positive (PML/RARα +)
APL treated at our centre with single agent ATO. 
Details of the treatment schedule with single agent
ATO, the supportive care administered, and the indica-
tions for the administration of hydroxyurea or an anthra-
cycline in induction was as reported earlier by our group.2
Cytogenetic analyses were carried out in the
Cytogenetics Unit of the institution. Karyotypes were
designated according to the International System for
Human Cytogenetic Nomenclature.9
FLT3-ITD and D835V point mutation analyses were
carried out on archival genomic DNA or cDNA samples
obtained at the time of diagnosis. With the exception of
minor variations in the primers for amplifying the cDNA
(forward: 5’-CAATTTAGGTATGAAAGCCAG-3’,
reverse: 5’-CTTTCAGCA TTTTGACGGCAACC-3’) the
rest of the procedure was based on standard established
methods.10
Of the 98 patients, archival DNA samples were not
available for 4 patients. Of the remaining 94 patients, a
FLT3 mutation was identified in 31 (33%). Of these, FLT3-
ITD was seen in 20 (21.3%) patients and a point mutation
of codon D835V was seen in 11 (11.7%). None of the
patients had both the FLT3-ITD and the D835V mutation.
Baseline characteristics of patients with and without a
FLT3 mutation are summarized in Table 1. Patients with
FLT3 activating mutations had a trend towards a higher
white cell count at presentation (p=0.073) and were sig-
nificantly more likely to have the bcr3 PML/RARα iso-
form (p=0.012). For further analysis of the impact of these
mutations on outcomes, patients with either a FLT3-ITD
mutation or a D835V mutation were combined and com-
pared with the cohort that did not have a FLT3 mutation.  
Of the 98 patients evaluated, karyotyping was per-
formed in 86 (87.8%). The karyotype failed in 5 (5.1%)
and in 12 (12.2%) there were inadequate metaphases
with a normal karyotype in the available metaphases. Of
the remaining 69 patients, an isolated t(15;17) karyotype
was seen in 53 (76.8%) while additional cytogenetic
abnormalities were detected in 16 (23.2%). There were
no significant differences in the baseline characteristics
between these two groups (data not shown). Between the
group that had FLT3 activating mutation (FLT3-ITD and
D835V) and the group that did not, there was no signifi-
cant difference in response to therapy. The complete
hematologic response (CHR) rate was 87.1% and 90.5%
The mean time to CHR was 43.7±13 and 45.25±10.25
days respectively for patients with and without a FLT3
mutation. 
We had earlier reported that the time at which the
majority of patients on this regimen achieved a molecular
remission (MR) was prior to initiation of consolidation
therapy.2 Of the 72 patients who had an RT-PCR at this
time point, 60.9% of patients with a FLT3 activating
mutation achieved MR versus 85.7% of those without
(p=0.022, RR=3.8; 95% CI 1.2 – 12.2). A univariate analy-
sis showed that only a low hemoglobin at diagnosis was
also associated with a significant delay in achieving an
MR (p=0.036, RR1.2; 95% CI 1.0–1.5). A multivariate
analysis adjusted for hemoglobin, WBC and platelet count
at diagnosis, only the presence of a FLT3 activating muta-
tion maintained its statistical significance (p=0.017,
RR=4.868; 95% CI 1.3 – 17.8). 
Table 1. Baseline characteristics of 94 patients evaluated for pres-
ence of FLT3 mutations.
Characteristic FLT3-ITD Heterozygous Wild Type p
Mean±SD/n (%) D835V Mean±SD/n (%) value
(n=20) Mean±SD/n (%) (n=63)
(n=11)
Age (years) 28.4±11.9 31.9±15.1 29.9±15.8 0.734
Sex: Male 7 (35.0) 5 (45.5) 36 (57.1) 0.209
Duration of symptoms  3.1±1.6 2.6±0.9 3.4±2.2 0.625
prior to diagnosis (weeks)  
Hb (g/L)    73±28 89±26 81±29 0.316
WBC (x 109/L)    18.2±25.5 17.9±21.4 8.0±21.4 0.073
Platelet (x 109/L) 30.1±46.7 35.1±51.9 28.4±34.4 0.580
High risk@ 5 (25.0) 3 (27.3) 18 (28.6) 0.952
PT – Prolonged 3 (15.0) 4 (36.4) 13 (20.6) 0.371
APTT – Prolonged − − 2 (3.2) 0.605
Abnormal liver function 5 (25.0) 4 (36.4) 11 (17.5) 0.332
test
LDH (IU/L) 619.3±228.2 722.9±437.1 590.3±373.3 0.225
Exposure to Anthracycline 2 (10.0) 3 (30.0) 8 (12.7) 0.289
Exposure to Hydroxyurea 15 (75.0) 8 (80) 50 (79.4) 0.911
Cytogenetics + # 1 (8.3) 2 (28.6) 13 (26.5) 0.390
RT-PCR
bcr 1 9 (45.0) 5 (45.5) 45 (71.4) 0.047
bcr 2 − 2 (18.2) 5 (7.9) 0.176
bcr 3 11 (55.0) 4 (36.4) 13 (20.6) 0.012
@risk stratification as previously defined by our group;2 #defined by the
presence of an additional cytogenetic anomaly.  
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At a median follow up of 20 months (range: 4 – 97), the
3 year Kaplan-Meier estimate (± 1SE) of OS, EFS and DFS
for patients with a FLT3 mutation was 82.51±7.24,
77.01±8.6, 88.82±7.48 percent, while for those without a
FLT3 mutation it was 92.06±3.4, 80.45±5.86, 89.02±5.31
percent. Statistical analysis of these survival curves by a
log rank test did not reveal any significant difference
between the two groups. Figure 1 illustrates the impact of
FLT3 activating mutation status on the OS and EFS in this
study.  The impact of FLT3-ITD and D835V mutations on
OS, EFS and DFS were also analyzed independently and
found not to be significantly different from each other
and from the group without a FLT3 activating mutation
(data not shown).   
Of the 69 patients who were evaluated for the impact
of cytogenetic findings, the presence of an additional
cytogenetic finding in 16 (23.2%) did not alter the CHR,
time to achieving CHR, time to MR, EFS, DFS or OS (data
not shown). 
This retrospective analysis suggests that neither the
presence of a FLT3 activating mutation nor that of an
additional cytogenetic finding appears to alter the clinical
outcome of newly diagnosed patients with APL treated
with single agent ATO in the short term. 
In spite of the association of the FLT3 mutation with
higher white cell counts, which is known to be the single
most important predictor of outcome,2 there was no dif-
ference in the EFS, DFS or OS in this study. Whether ATO
is a specific or non-specific inhibitor of FLT3 tyrosine
kinase activity remains to be demonstrated. Larger,
preferably randomized controlled trials would be
required to study if ATO has a beneficial effect in the sub-
set of patients with newly diagnosed APL who have a
FLT3 activating mutation. 
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Figure 1. Kaplan-Meier product limit estimate of event free sur-
vival (EFS), based on FLT3 mutation status (n=94). 
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